CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 2, 2018-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that NASDAQ has halted trading of the company’s common stock.

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 23, 2018-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a conference call and live webcast on

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 3, 2018-- Sage Therapeutics  (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on October 1, 2018 , the Compensation Committee of Sage’s

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 6, 2018-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the Morgan Stanley 16th Annual

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 6, 2018-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on September 4, 2018 , the Compensation Committee of

Results from pivotal trials consistently showed treatment with brexanolone injection provided significant and rapid reduction in depressive symptoms within days of initiating therapy Treatment response was durable over the follow-up period, across three placebo-controlled trials ZULRESSO™

Conditional acceptance granted by U.S. Food and Drug Administration ( FDA ) for the proprietary name ZULRESSO™ for Sage’s intravenous formulation of brexanolone Continuing to execute commercial build and launch readiness for ZULRESSO™ (brexanolone injection) in postpartum depression ahead of PDUFA

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 3, 2018-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on August 1, 2018 , the Compensation Committee of Sage’s

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 1, 2018-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the Canaccord 38th Annual

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 24, 2018-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a conference call and live webcast on